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Identity 
Other names: DYRK, DYRK1, HP86, MNB, MNBH 
HGNC (Hugo): DYRK1A 
Location: 21q22.13 
Local order: 
Genes surrounding DYRK1A and their chromosome 
locations ordered from centromere to telomere 
(according to NCBI Map Viewer): 
- TTC3 (tetratricopeptide repeat domain 3). Location 
21q22.13. 
- DSCR9 (Down syndrome critical region gene 9; 
miscRNA, non-protein coding). Location 21q22.13. 
- DSCR3 (Down syndrome critical region gene 3). 
Location 21q22.13. 
- DYRK1A . Location 21q22.13. 
- LOC100289229 (hypothetical gene). Location 
21q22.13. 
- KCNJ6 (potassium inwardly-rectifying channel, 
subfamily J, member 6). Location: 21q22.1; 21q22.1. 
- DSCR4 (Down syndrome critical region gene 4). 
Location 21q22.2. 
- DSCR8 (Down syndrome critical region gene 8; 
miscRNA). Location 21q22.2. 
Note 
The chromosomal region depicted in the above figure is 
part of the "critical region" for Down syndrome, 
commonly named Down syndrome critical region 
(DSCR). This region, which encompasses 5.4 Mb of 
chromosome 21 and contains around 30 genes, has 
been defined in phenotype-genotype correlation studies 
of individuals with partial trisomy 21 (Delabar et al., 
1993). Similar correlation studies of patients with 
partial monosomy 21 have defined a common region 
within DSCR that when deleted causes microcephaly 
and developmental delay. This region expands 1.2 Mb 
and contains 10 genes including DYRK1A (Matsumoto 
et al., 1997). The identification of two unrelated 
patients with microcephaly carrying a DYRK1A 
truncated mutation in hemizygosis (see bellow; Moller 
et al., 2007) indicates that haploinsufficiency of 
DYRK1A is most likely the cause of the common 
features presented by these two patients and by patients 
with partial monosomy 21. 
 
Map of the Chromosomal region in 21q22.13 - 21q22.2 where DYRK1A is located. Genes (in green) and predicted gene (in black) 
surrounding DYRK1A are depicted according to the chromosomal position in NCBI Map Viewer (version released in August 2009). 
Direction of the arrowhead indicates the orientation of the gene. 
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Schematic representation of the exon-intron organization of human DYRK1A gene. The size of introns and exons is in kb. Exons 
(boxes) are numbered and drawn to scale: in orange, coding exons; in blue, alternative first exons. The position of major transcription 
start sites (TSSs) according to Maenz et al. (2008) is indicated with blue arrows. Alternative splicing events are shown with dotted lines 




The DYRK1A gene contains at least 12 exons spanning 
approximately 149.7 kb of genomic DNA. 
Transcription 
Several transcripts have been identified as result of 
alternative splicing (Wang et al., 1998; Guimerá et al., 
1999; Maenz et al., 2008). The use of two alternative 
first exons, controlled by different promoter sequences, 
does not affect the open reading frame (alternative 
splicing events a and b). These two promoters differ in 
their strength and regulation by the transcription factor 
E2F1 (Maenz et al., 2008). Exclusion of exon 2 would 
give rise to a N-terminal truncated protein (alternative 
splicing event c). The use of an alternative acceptor si e 
within exon 4 (alternative splicing events d and e) 
generates two protein variants that differ by the 
inclusion/exclusion of 9 amino acids in the N-terminal 
region (Kentrup et al., 1996; Guimerá et al., 1999). No 
functional differences have been associated to any of 
these variants. Further splice variants, affecting he C-
terminal region, were identified by PCR cloning 
(Guimerá et al., 1999), although the existence of the 
protein isoforms encoded by these transcripts has not 
yet been confirmed. 
Pseudogene 
No pseudogene reported. 
Protein 
Description 
The DYRK1A gene encodes two main protein isoforms 
of 763 and 754 amino acids. DYRK1A is a protein 
kinase that belongs to the DYRK family of dual-
specificity protein kinases (CMGC group: DYRK 
family: DYRK subfamily). The kinase domain is 
located centrally in the primary structure of the protein. 
DYRK1A shares with the other DYRKs a conserved 
motif N-terminal to the kinase domain known as 
DYRK homology (DH)-box. It also harbors a 
functional, bipartite nuclear localization signal (NLS) 
N-terminal to the DH-box, a second NLS between 
subdomains X and XI within the kinase domain, a C-
terminal PEST motif, and a polyhistidine tract that ac s 
as a nuclear speckle targeting signal. When analyzed by  
Western blot with antibodies raised against the C-
terminal, the protein appears as three bands around 90 
kDa. 
Expression 
At the RNA level, DYRK1A is expressed as an 
approximately 6 kb transcript in many fetal and adult 
tissues including brain, heart, lung and skeletal muscle 
(Guimerá et al., 1996; Shindoh et al., 1996; Song et al., 
1996). At the protein level, human DYRK1A 
expression has been mainly studied in the central 
nervous system, where it is detected in cortex, 
hippocampus, amygdala, thalamus and substantia nigr
(Wegiel et al., 2004). The number of DYRK1A 
immunopositive neurons increases with maturation of 
human brain and an increase in the number of 
DYRK1A-positive astrocytes in aged people has also 
been observed (Weigel et al., 2004). Work done in 
mice has led to the proposal that Dyrk1a is expressed in 
sequential phases of central nervous system 
development; i) scattered expression in individual pre-
neurogenic progenitors; ii) throughout the cell cycle in 
neurogenic progenitors; ii) down-regulated in post-
mitotic neurons as they migrate radially; and iv) 
sustained expression in late differentiating neurons 
(Hammerle et al., 2008). Based on these observations, 
DYRK1A has been suggested to be critical for the 
coupling of the sequential events required for prope  
neuronal development. 
The analysis of the human DYRK1A promoter found 
two promoter regions that respond differentially to the 
cell cycle-related transcription factor E2F1 (Maenz et 
al., 2008). Binding of the AP4-geminin complex to the 
human DYRK1A promoter has been shown by 
chromatin immunoprecipitation assays; moreover, the 
DYRK1A promoter is downregulated by AP4 
overexpression in gene reporter assays, suggesting that 
the AP4-geminin repressor complex could be 
responsible of the DYRK1A downregulation in non-
neuronal cells (Kim et al., 2004). In mice, Dyrk1a is 
transcriptionally induced by the receptor activator of 
nuclear factor kappa-B ligand (RANKL) cytokine 
through the activity of the nuclear factor of activa ed T-
cells (NFAT) transcription factors (Lee et al., 2009). 
Localisation 
When overexpressed in mammalian cells, DYRK1A 
protein mainly localizes in the nucleus and shows a 
punctuated staining that it is  
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Schematic representation of DYRK1A protein. NLS: nuclear localization signal. DH: DYRK-homology box. PEST: Pest motif. His: 
Polyhistidine stretch. S/T: Serine and threonine-rich region. The line shows the alternatively spliced segment of 9 amino acids. 
 
compatible with its accumulation in nuclear speckles 
(or splicing factor compartment) (Becker et al., 1998; 
Alvarez et al., 2003). Two nuclear localization signals 
contribute to DYRK1A nuclear translocation and the 
histidine stretch is responsible for the accumulation of 
the protein in nuclear speckles (Alvarez et al., 2003). 
Endogenous DYRK1A is detected in both the nucleus 
and the cytosol of human neurons, but only in the 
cytosol of astrocytes (Wegiel et al., 2004). Within the 
cytosol, DYRK1A accumulates in the cell bodies, 
dendrites and synapses (Wegiel et al., 2004). Similar 
behaviour has been described for mouse and chicken 
Dyrk1a (Marti et al., 2003; Hammerle et al., 2003; 
Laguna et al., 2008). These findings also correlate wi h 
the observed nuclear-cytosolic partitioning of Dyrk1a 
in mouse brain by biochemical fractionation (Aranda et 
al., 2008). 
In certain pathological situations like the 
neurodegeneration associated to sporadic Alzheimer's 
disease and Down syndrome, DYRK1A is detected in 
neurofibrillary tangles, in granules in granulovacuolar 
degeneration and in corpora amylacea (Wegiel et al., 
2008). 
Function 
DYRK1A is a dual-specificity protein kinase that 
autophosphorylates on tyrosine serine and threonine 
residues, but phosphorylate substrates only on serie or 
threonine residues. Autophosphorylation of Tyr 
312/321 (754/763 variants) in the activation loop is 
required for full catalytic activity (Himpel et al., 2001; 
Lochhed et al., 2005). A full list of the residues 
phosphorylated in DYRK1A can be found at 
PhoSphositePlus. A consensus phosphorylation 
sequence has been proposed for DYRK1A (RPXS/TP) 
(Himpel et al., 2000), although some phosphorylation 
sites have been found that do not fit within the 
consensus such as in the case of LTAT(434)P in 
SF3B1/SAP155 or RPAS(640)V in glycogen synthase 
(Skurat et al., 2004; de Graaf et al., 2006). 
The phenotypic analysis of a loss-of-function mouse 
model has provided information about DYRK1A 
functional roles. Null Dyrk1a embryos present a sever  
developmental delay and die around embryonic day 
10.5, and the analysis of the heterozygous animals has 
indicated that DYRK1A plays a role in brain 
development (Fotaki et al., 2002). In this context, 
DYRK1A has been shown to participate in 
neuritogenesis (Benavides-Piccione et al., 2005; 
Gockler et al., 2009; Lepagnol-Bestel et al., 2009; 
Scales et al., 2009), and DYRK1A overexpression 
potentiates nerve growth factor (NGF)-mediated 
neuronal differentiation in PC12 cells through an 
enhancement of Ras/MAPK signalling (Kelly and 
Ramahni, 2005) or exit from the cell cycle in neuronal 
progenitors (Park et al., 2010; Yabut et al., 2010). 
Furthermore, an increase in DYRK1A gene dosage 
alters the levels of neuron-restrictive silencer factor 
(NRSF or REST), a key regulator of neuronal 
differentiation (Canzonetta et al., 2008). In the adult 
brain, DYRK1A regulates epidermal growth factor 
(EGF) signalling in stem cell daughters and reduced 
levels of DYRK1A compromise stem cell longevity 
(Ferron et al., 2010). These evidences together with
DYRK1A overexpression in Down syndrome 
individuals (Dowjat et al., 2007) and the phenotype of 
mouse models of overexpression (Smith et al., 1997; 
Altafaj et al., 2001; Ahn et al., 2006), have led to the 
proposal of DYRK1A as a main contributor to Down 
syndrome neurological alterations (reviewed in Park et 
al., 2009a). Finally, there are increasing evidences of a 
link of DYRK1A with neurodegeneration, given that it 
phosphorylates several proteins related to this cellular 
process including tau, alpha-synuclein, septin-4, 
presenilin or amyloid beta precursor protein (APP) and 
accumulates in amyloid lesions (reviewed in Park et al., 
2009b). 
Additionally, the participation of DYRK1A in different 
cellular processes and signal transduction pathways h s 
been inferred from the activity of its interactors and 
substrates. Functional activities include apoptosis, 
exerting a protective role through phosphorylation of 
caspase-9 or the deactelylase sirtuin-1 (SIRT1) (Seifert 
et al., 2008; Laguna et al., 2008; Guo et al., 2010); 
endocytosis, through the interaction and 
phosphorylation of the GTPase dynamin-1, the 
phosphatase synaptojanin-1 or the scaffold protein 
amphiphysin-1 (Murakami et al., 2009; and references 
therein); cytoskeletal-related processes, through 
phosphorylation of tau or microtubule-associated 
protein 1B (MAP1B) (Woods et al., 2001; Scales et al., 
2009); receptor tyrosine kinase-dependent signalling, 
through the interaction with the kinase B-Raf (NGF) or 
the inhibitor Sprouty-2 (FGF) (Kelly and Rahmani, 
2005; Aranda et al., 2008). 
A relevant group of DYRK1A substrates are chromatin 
regulators and transcription factors suggesting a role
for DYRK1A in the regulation of gene expression 
programs. When assayed in gene reporter assays, 
DYRK1A works as an activator of cAMP responsive 
element binding protein 1  
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Schematic representation of DYRK1A gene indicating the location of the breakpoints in chromosome 21 (vertical arrows) of the reported 
patients with a de novo balanced translocation. 
 
(CREB1) (Yang et al., 2001), Gli1 (Mao et al., 2002), 
forkhead box protein O1 (FOXO1/FKHR) (von Groote-
Bidlingmaier et al., 2003) or androgen receptor-
interacting protein 4 (ARIP4/RAD54L2) (Sitz et al., 
2004) and as an inhibitor of Notch-dependent 
transcription (Fernandez-Martinez et al., 2009). 
DYRK1A acts as negative regulator of NFAT 
transcription factors in distinct cellular environments 
by inducing their translocation to the cytosol (Arron et 
al., 2006; Kuhn et al., 2009; Lee et al., 2009). 
DYRK1A cooperation with glycogen synthase kinase 3 
(GSK3) promotes the degradation of cryptochrome 2 
(CRY2), thus contributing to the internal cellular clock 
(Kurabayashi et al., 2010). Another DYRK1A target is 
the tumour protein p53, either by being a direct 
DYRK1A substrate or indirectly through the 
phosphorylation by DYRK1A of the p53 deactelylase 
SIRT1 (Guo et al., 2010; Park et al., 2010). Finally, 
DYRK1A has been proposed as a regulator of splicing 
based on DYRK1A localization in nuclear speckles 
(Alvarez et al., 2003) and on having several splicing 
factors such SF3b1 or ASF as substrates (de Graaf et 
al., 2006; Shi et al., 2008). In fact, DYRK1A 
phosphorylation of the alternative splicing factor ASF 
prevents ASF-mediated inclusion of the alternatively 
spliced exon 10 in tau mRNA (Shi et al., 2008). 
Homology 
Mouse and human DYRK1A show a high degree of 
homology at the amino acid level (99%). The 
Drosophila DYRK1A orthologue is the minibrain gene 
(Tejedor et al., 1995). Within the DYRK family of 
kinases, the closest paralogous is DYRK1B. 
Mutations 
Note 
A truncated mutation in DYRK1A gene has been 
identified in two unrelated patients that present prenatal 
onset of microcephaly, intrauterine growth retardation, 
developmental delay, severe feeding problems and 
febrile seizures. In both patients, truncation of 
DYRK1A results from a de novo balanced 
translocation involving chromosome 21, 
t(9;21)(p12;q22) in one patient and t(2;21)(q22;q22) in 
the other (Moller et al., 2008). Location of the 






Various types of cancer and disease 
Disease 
There are evidences suggesting a role of DYRK1A in 
several human diseases. All the evidences, with the 
exception of those reported in Moller et al. (2008) 
regarding microcephaly, are based on in vitro 
molecular and biochemical studies, on RNA expression 
studies and on studies in model organisms, mainly in 
the mouse. The list of human diseases includes Down 
syndrome (reviewed in Hammerle et al., 2003; Park et 
al., 2009a), early onset microcephaly (Moller et al.,
2008), Alzheimer and Huntington diseases (reviewed in 
Park et al., 2009b), several cancer types (Baek et al., 
2009; de Wit et al., 2002) and cardiac hypertrophy 
(Khun at al., 2009; Raaf et al., 2009). 
Oncogenesis 
Experiments performed in the Ts65Dn trisomic mouse 
model for Down syndrome have shown that 
overexpression of DYRK1A contributes to the 
attenuation of the calcineurin pathway induced by the 
increased dosage of RCAN1 (also named DSCR1), a 
chromosome 21 gene that like DYRK1A is triplicated 
in this model (Baek et al., 2009). The reduction in 
calcineurin signalling leads to a significant reduction of 
angiogenesis and tumour growth. Because the 
incidence of many cancer types is significantly reduced 
in people with Down syndrome (complete trisomy of 
chromosome 21), the results obtained in mice suggest 
that small differences in the amount of DYRK1A 
kinase could, through the calcineurin-dependent 
regulation of angiogenesis, modify the growth of some 
type of tumours also in humans (Pussegoda et al., 
2010). By contrary, phosphorylation of caspase-9 by 
DYRK1A may have a negative role in cancer because a 
reduction of caspase-9 apoptotic activity protects 
mitotic cells from apoptosis and promotes cell survival 
during tumorigenesis (Allan and Clarke, 2007). 
DYRK1A has been shown to interact with two viral 
oncoproteins, adenovirus E1A and human papilloma 
virus (HPV) E7 (Zhang et al., 2001; Liang et al., 2008; 
Komorek et al., 2010), which could be suggestive of 
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Melanoma 
Note 
DYRK1A mRNA levels in a melanoma cell line with 
high metastatic potential (Mel57) are lower than in a 
melanoma cell line (1F6) with poor metastatic 
potential. DYRK1A mRNA levels are down-regulated 
in vivo during melanocytic tumour progression, and i  
tumour samples from lung, oesophagus, colon, 
pancreas and testis when compared to normal samples 
from the same tissues (de Wit et al., 2002). 
Cervical cancer 
Note 
HPV type 16 (HPV16) is a tumorigenic virus that 
causes the development of cervical cancer. DYRK1A is 
present in HPV16 immortalized keratinocytes but not
in primary keratynocytes; moreover, malignant cervical 
lesions contain more DYRK1A than normal tissue 
(Chang et al., 2007). Biochemical data lead to the 
suggestion that the increased expression of DYRK1A 
in immortalized keratinocytes and in cervical tissue  
acts as an antiapoptotic factor in the FKHR-dependent 
pathway leading to tumour development (Chang et al., 
2007). Additionally, DYRK1A interacts and 
phosphorylates the HPV16 protein E7 leading to its 
stabilization and to an increase in its capacity for
forming clones in a colony-formation assay (Liang et 
al., 2008). 
Pancreatic endocrine neoplasms 
Note 
Microarray hybridization data showed up-regulation of 
DYRK1A in metastatic pancreatic endocrine 
neoplasms when compared with nonmetastatic 
pancreatic endocrine neoplasms (Hansel et al., 2004). 
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